Medical Cannabis Favored to Treat MS Spasticity and Other Ills by Doctors in Australia, Survey Finds
Most general practitioners in Australia favor prescribing medical cannabis to treat spasticity in MS or pain in select other diseases. But general practitioners are not allowed to under current laws, and they say they know little about its use, according to results of a national survey.
A study based on its findings, “Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey,” was published in the British Medical Journal Open.
It’s not brand new news that a person’s environment can play a role in the development of MS. It’s also not unheard of that exposure to paint fumes and the like can be detrimental to your health. But this study reports a specific link between solvents and MS risk. It suggests it may have to do with lung irritation producing an autoimmune response, which can trigger MS.
Exposure to organic solvents such as paint or varnish greatly raises the risk of MS, particularly in people who smoke or have a genetic susceptibility to the disease, a large-scale Swedish study reports.
In fact, solvent exposure — linked to occupation, like being a painter or working in a paint factory — raised risk by 50 percent compared to those with no such long-term exposure, and was higher still when smoking or genes also came into play. The exposure times — the number of years a person worked with paints or varnish — was not defined by the researchers.
On the other hand, here’s a study of other environmental pollutants with a different conclusion.
Long-term exposure to three common air pollutants — fine particulate matter, nitrogen dioxide, and ozone — were not found to be “convincingly” linked to incidence of MS in a large population study conducted in Canada.
The study, “Long-term exposure to air pollution and the incidence of multiple sclerosis: A population-based cohort study,” was published in the journal Environmental Research.
NICE is the group that recommends healthcare treatments in England and Wales based on cost-effectiveness. Earlier this year, NICE cleared Ocrevus (ocrelizumab) for RRMS, after first turning thumbs down. NICE reversed itself because it was able to work out a deal lowering the disease-modifying therapy’s price. Let’s hope it can work out the same deal so that it will allow Ocrevus to be used as a primary progressive MS (PPMS) treatment.
The National Health Service (NHS) is the subsidized, publicly-funded healthcare system for England, with similar structures in other parts of the U.K. A positive NICE opinion obligates the service to offer the therapy at no or low cost.
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.